- The Nasdaq has granted to the medicine company OpGen ( NASDAQ: OPGN ) a 180-day extension to regain compliance with the stock exchange's minimum bid price requirement.
- OpGen now has until Feb. 27, 2023, to regain compliance.
- The compliance will be regained if at any time until Feb. 27, 2023, the bid price per share closes at or above $1.00 for a minimum of 10 consecutive trading days.
- OPGN shares were trading -0.60% pre-market.
- Source: Press Release
For further details see:
Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement